<em>ERCC1</em> and <em>XRCC1</em> but not <em>XPA</em> single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma

Abstract

Our study aimed to investigate the correlation between single nucleotide polymorphisms of <i>ERCC1/XRCC1/XPA</i> genes and postoperative chemotherapy efficacy and prognosis of endometrial carcinoma. Our study included 108 patients with endometrial carcinoma and 100 healthy participants. <i>ERCC1</i> rs11615/<i>XRCC1</i> rs25487/<i>XPA</i> rs1800975 gene polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism. Then the chemotherapy efficacy and toxic effects of the patients were assessed. The genotype and allele frequency of <i>ERCC1</i> rs11615/<i>XRCC1</i> rs25487 in the case group were significantly different from that in the control group (all <i>P</i><0.05). The patients with AA + GA in <i>ERCC1</i> rs11615 had an increased risk of endometrial carcinoma than those with GG, and the risk of endometrial carcinoma for patients with AA + GA was also higher in comparison with patients with GG genotype in <i>XRCC1</i> rs25487 (all <i>P</i><0.05). GG on both <i>ERCC1</i> rs11615/<i>XRCC1</i> rs25487 had a higher effective rate of chemotherapy than GA + AA (all <i>P</i><0.05). <i>ERCC1</i> rs11615/<i>XRCC1</i> rs25487 gene polymorphisms were linked with toxic effects in liver, kidney, and nervous system. <i>ERCC1</i> rs11615/<i>XRCC1</i> rs25487, muscular invasion, and tumor stage were independent risk factors for the prognosis of endometrial carcinoma (all <i>P</i><0.05). However, no significant associations were observed between <i>XPA</i> rs1800975 polymorphism and chemotherapy efficacy and prognosis of endometrial carcinoma (all <i>P</i>>0.05). These results indicated that <i>ERCC1</i> and <i>XRCC1</i> but not <i>XPA</i> polymorphisms correlate with response to chemotherapy in endometrial carcinoma.